Assessment of Ventricular Arrhythmia Risk After CRT-D Replacement for Patients With Primary Prevention Indication

CompletedOBSERVATIONAL
Enrollment

289

Participants

Timeline

Start Date

June 9, 2015

Primary Completion Date

February 12, 2020

Study Completion Date

February 12, 2020

Conditions
Cardiac ResynchronizationBiventricular Pacemakers, ArtificialCardioverter-Defibrillators, ImplantableDevice Replacement
Interventions
DEVICE

CRT-D device replacement

Trial Locations (37)

31403

CHU Toulouse, Toulouse

Unknown

OLV Aalst, Aalst

CH d'Annecy, Annecy

Hôpital de la Cavale Blanche, Brest

CHU Caen, Caen

CHU Montpied, Clermont-Ferrand

CH Du Bocage, Dijon

CHRU de Lille, Lille

CHU de Limoges, Limoges

CH Saint Philibert, Lomme

Cliniques du Tonkin, de la Sauvegarde et Protestante, Lyon

Clinique Clairval, Marseille

Hôpital de la Timone, Marseille

Hôpital Mercy, Metz

CHU Montpellier, Montpellier

CHU Nancy, Nancy

Nouvelles Cliniques Nantaises, Nantes

CH de la Pitié Salpétrière, Paris

CHU Pessac, Pessac

CHU de Rennes, Rennes

CHU Hôpital CHarles Nicolle, Rouen

CH de Saint-Etienne, Saint-Etienne

CHU Tours, Tours

Schuechtermann-Klinik, Bad Rothenfelde

Stadtisches Klinikum Brandenburg, Brandenburg

DRK-Krankenhaus Moelln Ratzeburg, Ratzeburg

Cardiological Praxis, Rostock

Semmelweis University, Budapest

Barzilai Medical Center, Ashkelon

Ospedale Versilia, Lido di Camaiore

Clinica Mediterranea, Napoli

Ospedale Santa Chiara, Pisa

Hospital de Santa Maria, Lisbon

Hospital de Santa Marta, Lisbon

Hospital Universitario de Burgos, Burgos

Hospital Universitario Marques de Valdecilla, Santander

Hospital Clinico Universitario de Valladolid, Valladolid

All Listed Sponsors
lead

Biotronik SE & Co. KG

INDUSTRY

NCT02323503 - Assessment of Ventricular Arrhythmia Risk After CRT-D Replacement for Patients With Primary Prevention Indication | Biotech Hunter | Biotech Hunter